Biologic response (antiviral) to recombinant human interferon alpha 2a as a aunction of dose and route of administration in healthy volunteers | Zendy

Witter Frank | Zendy; Barouki Florence | Zendy; Griffin Diane | Zendy; Nadler Paul | Zendy; Woods Amina | Zendy; Wood Debra | Zendy; Lietman Paul | Zendy

Premium

Biologic response (antiviral) to recombinant human interferon alpha 2a as a aunction of dose and route of administration in healthy volunteers

Author(s) -

Witter Frank,

Barouki Florence,

Griffin Diane,

Nadler Paul,

Woods Amina,

Wood Debra,

Lietman Paul

Publication year - 1987

Publication title -

clinical pharmacology and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.941

H-Index - 188

eISSN - 1532-6535

pISSN - 0009-9236

DOI - 10.1038/clpt.1987.198

Subject(s) - vesicular stomatitis virus , recombinant dna , pharmacology , medicine , intramuscular injection , peripheral blood mononuclear cell , alpha interferon , vesicular stomatitis indiana virus , interferon , stomatitis , virus , immunology , virology , in vitro , biology , biochemistry , gene

The kinetics of the antiviral effect of intramuscular and intravenous injections of recombinant human interferon α 2a were investigated in healthy volunteers. Cohorts of eight to 11 subjects received single intramuscular injections of either 0.3 × 10 6 , 3 × 10 6 , or 18 × 10 6 U or an intravenous infusion of 18 × 10 6 U over 30 minutes. Serial samples of peripheral blood mononuclear cells were analyzed for antiviral effects including both (2'‐5') oligoadenylate synthetase activity and resistance to vesicular stomatitis virus infection in vitro. A dose‐response relationship was established between recombinant human interferon α 2a dose and both vesicular stomatitis virus resistance and (2'‐5') oligoadenylate synthetase activity. At the 0.3 × 10 6 U dose an antiviral effect occurred without clinical side effects. The presence of clinical side effects is not necessary for an antiviral effect. Clinical Pharmacology and Therapeutics (1987) 42, 567–575; doi: 10.1038/clpt.1987.198

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research